XAB06, a glyco-humanized broad-spectrum anti-<i>Pseudomonas aeruginosa</i> polyclonal antibody, protects mice in a lethal sepsis model. [PDF]
Royer P-J +5 more
europepmc +1 more source
Performance evaluation of clinical diagnostic kits for Group B <i>Streptococcus</i> available in China. [PDF]
Su R +14 more
europepmc +1 more source
Optimizing adult pneumococcal vaccination in India: Evidence from serotype surveillance. [PDF]
Isaac TB +4 more
europepmc +1 more source
Pneumococcal nasopharyngeal carriage, serotype distribution, and vaccination status in hospitalized children in Latvia: A cross-sectional study during the post-PCV13, pre-PCV15/PCV20 transition period. [PDF]
Cupeca H +9 more
europepmc +1 more source
Serotyping and Seroprevalence Estimation of Pasteurellosis in Ovine and Caprine in Selected Districts of Afar Region, Ethiopia. [PDF]
Dubie T +8 more
europepmc +1 more source
Design of a tetravalent dengue vaccine incorporating T-cell epitopes from NS3 and NS5 proteins and B-cell epitopes from the envelope protein using an immunoinformatics approach. [PDF]
Dobutr T, Srifa P, Pinpathomrat N.
europepmc +1 more source
Safety and Immunogenicity of the Live-Attenuated Quadrivalent Dengue Vaccine V181 Compared With Butantan-DV Among Healthy Adults in Brazil: A Randomized, Double-Blind, Phase 2 Trial. [PDF]
Alexanderian D +10 more
europepmc +1 more source
Recommendations for Adult Pneumococcal Vaccination in Korea: 2026 Update Incorporating the 21-Valent Pneumococcal Conjugate Vaccine. [PDF]
Song JY +10 more
europepmc +1 more source
Parameters Affecting Dengue Virus Replication in Vero Cells. [PDF]
Asim MMH +14 more
europepmc +1 more source
Open-label, randomised controlled, multicentre study evaluating higher valency pneumococcal vaccines (PCV15/PCV20) compared with PCV13 given in homologous schedules at 3 months and 12 months ('1+1' schedule) and 2 months, 4 months and 12 months ('2+1' schedule) in infants: protocol. [PDF]
Aslam R +19 more
europepmc +1 more source

